Greenwich LifeSciences (GLSI) Earnings Date & Reports

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

GLSI is expected to report earnings to rise 24.07% to -33 cents per share on November 16

Greenwich LifeSciences GLSI Stock Earnings Reports

Q3'26

Est.

$-0.34

Q2'26

Beat

by $0.06

Q1'26

Est.

$-0.33

Q4'25

Beat

by $0.02

Q3'25

Missed

by $0.10

The last earnings report on August 31 showed earnings per share of -27 cents, beating the estimate of -33 cents. With 36.15K shares outstanding, the current market capitalization sits at 226.04M.

View a ticker or compare two or three

GLSI

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for GLSI